Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 48

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 48
---
     |         |  (37,172 | ) |     |   |    28.57 | % |
| Income tax provision                                      |     |                             |        - |   |     |         |    0.00 | % |     |        |        - |   |     |         |    0.00 | % |     |         |        - |   |     |   |      n/a |   |
| Net loss                                                  |     | $                           | (167,292 | ) |     |         | -283.23 | % |     | $      | (130,120 | ) |     |         | -220.30 | % |     | $       |  (37,172 | ) |     |   |    28.57 | % |

<div align='center'>35</div>

Revenues

Revenues from continuing operations were $59,065 for the three months ended June 30, 2025 and $59,064 for the same period ended 2024. $27,425 of revenue from related parties recognized during the three months ended June 30, 2025 and consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. as did $27,425 for the period ended 2024. $31,640 of revenue recognized during both of the three months ended June 30, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Operating Expenses

Operating Expense were $99,824 for the three months ended June 30, 2025 and $ 167,032 for the same period ended 2024. The primarily operating expense for 2025 consists of $ 46,625 of Consulting & Professional expenses. In the same period in previous year Consulting and Professional fees expenditure were $95,539. During the period ended 2024 research and development expenses amounted to $32,500 constituting the second largest expense recognized during that quarter.

Other Income

For the three months ended June 30 2025, the Company reported a net other expense of $(126,526) whereas in the same period ended 2024 the Company reported the net other expense of $(22,154). Net other expense for the quarter ended 2025 was primarily driven by the recognition of a Derivative Loss of $(89,259). For the quarter ended June 30, 2025 the Company also recognized higher interest and amort